Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Björn Nashan

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
Health Care Science|November 3, 2025
Lung Xenotransplantation Advances in the Context of Clinical Pandora's Box-Positioned Amid Innovations in Heart, Kidney, and Liver XenograftsBjörn Nashan
World Journal of Surgery|August 30, 2014
mTOR inhibitors and their role in modern concepts of immunosuppressionBjörn Nashan
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 5, 2005
Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative reviewBjörn Nashan
Transplantation Reviews (Orlando, Fla.)|November 26, 2008
Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?Björn Nashan
Clinical Transplantation|August 6, 2013
Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patientsBjörn Nashan
Transplantation|April 29, 2004
Renal allograft allocation for children: are we penalizing children to not penalize adults?Björn Nashan
Expert Opinion on Investigational Drugs|November 30, 2002
Review of the proliferation inhibitor everolimusBjörn Nashan
Health Care Science|December 26, 2025
The First Clinical Renal Xenotransplantation Study (EXPAND): Evaluating Safety, Function, and Zoonotic RisksBjörn Nashan
Transplantation|December 27, 2023
Assessment and Evaluation for Patients With Alcohol Use Disorder: The German Allocation PolicyBjörn Nashan
Transplant International : Official Journal of the European Society for Organ Transplantation|June 29, 2004
Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitorsBjörn Nashan
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Health Care Science|November 3, 2025
Lung Xenotransplantation Advances in the Context of Clinical Pandora's Box-Positioned Amid Innovations in Heart, Kidney, and Liver XenograftsBjörn Nashan
World Journal of Surgery|August 30, 2014
mTOR inhibitors and their role in modern concepts of immunosuppressionBjörn Nashan
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 5, 2005
Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative reviewBjörn Nashan
Transplantation Reviews (Orlando, Fla.)|November 26, 2008
Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?Björn Nashan
Clinical Transplantation|August 6, 2013
Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patientsBjörn Nashan
Transplantation|April 29, 2004
Renal allograft allocation for children: are we penalizing children to not penalize adults?Björn Nashan
Expert Opinion on Investigational Drugs|November 30, 2002
Review of the proliferation inhibitor everolimusBjörn Nashan
Health Care Science|December 26, 2025
The First Clinical Renal Xenotransplantation Study (EXPAND): Evaluating Safety, Function, and Zoonotic RisksBjörn Nashan
Transplantation|December 27, 2023
Assessment and Evaluation for Patients With Alcohol Use Disorder: The German Allocation PolicyBjörn Nashan
Transplant International : Official Journal of the European Society for Organ Transplantation|June 29, 2004
Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitorsBjörn Nashan
Pageof 19